SOMATIC THERAPY FOR MAJOR DEPRESSIVE DISORDER - SELECTION OF AN ANTIDEPRESSANT

被引:0
|
作者
PRESKORN, SH [1 ]
BURKE, M [1 ]
机构
[1] UNIV KANSAS, SCH MED, DEPT PSYCHIAT, WICHITA, KS USA
关键词
D O I
暂无
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Major depressive disorder is a major health concern. It adversely affects the patient, the family, and society. While the consequences can be devastating and life-threatening, this condition has an excellent prognosis when properly identified and treated. Somatic therapy plays a pivotal role in inducing and maintaining a remission and preventing recurrent attacks. There are now five major classes of antidepressants which differ in terms of their clinical spectra of antidepressant activity, their safety and tolerability, their likelihood of pharmacodynamic and pharmacokinetic interactions with concomitantly prescribed drugs, ease of administration, and physician confidence, which is in large measure a reflection of the extent and quality of their human exposure database. The proper selection and management of antidepressant pharmacotherapy is based on an understanding of these differences.
引用
收藏
页码:5 / 18
页数:14
相关论文
共 50 条
  • [1] Modafinil as antidepressant augmentation therapy in major depressive disorder
    Thase, ME
    DeBattista, C
    Fava, M
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S210 - S211
  • [2] The impact of premature discontinuation of antidepressant therapy in major depressive disorder
    Earnshaw, S
    Krishnan, A
    Hogue, SL
    Williams, J
    VALUE IN HEALTH, 2004, 7 (03) : 267 - 267
  • [3] Valproate as an antidepressant in major depressive disorder
    Davis, LL
    Kabel, D
    Patel, D
    Choate, AD
    FoslienNash, C
    Gurguis, GNM
    Kramer, GL
    Petty, F
    PSYCHOPHARMACOLOGY BULLETIN, 1996, 32 (04) : 647 - 652
  • [4] Isokinetic muscle performance in major depressive disorder: Alterations by antidepressant therapy
    Bilici, M
    Koroglu, MA
    Cakirbay, H
    Guler, M
    Tosun, M
    Aydin, T
    Tan, U
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2001, 109 (3-4) : 149 - 164
  • [5] Combination antidepressant therapy for major depressive disorder: Speed and probability of remission
    Stewart, Jonathan W.
    McGrath, Patrick J.
    Blondeau, Claude
    Deliyannides, Deborah A.
    Hellerstein, David
    Norris, Sandhaya
    Amat, Jose
    Pilowsky, Daniel J.
    Tessier, Pierre
    Laberge, Louise
    O'Shea, Donna
    Chen, Ying
    Withers, Amy
    Bergeron, Richard
    Blier, Pierre
    JOURNAL OF PSYCHIATRIC RESEARCH, 2014, 52 : 7 - 14
  • [6] The impact of premature discontinuation of antidepressant therapy in major depressive disorder in the UK
    Beard, SM
    Earnshaw, SR
    Gaffney, L
    Hogue, SL
    Krishnan, AA
    VALUE IN HEALTH, 2004, 7 (06) : 779 - 779
  • [7] Isokinetic muscle performance in major depressive disorder: Alterations by antidepressant therapy
    Bilici, M
    Cakirbay, H
    Koroglu, MA
    Guler, M
    Tosun, M
    Aydin, T
    Tan, U
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2001, 110 (1-2) : 9 - 23
  • [8] Impact of Drug Tolerability on the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder
    Ginsberg, Lawrence D.
    CNS SPECTRUMS, 2009, 14 (12) : 8 - 14
  • [9] Valproic acid as an antidepressant in major depressive disorder
    Davis, LL
    Petty, F
    PSYCHOPHARMACOLOGY BULLETIN, 1996, 32 (03) : 430 - 430
  • [10] The Relationship of Antidepressant Therapy with Neuroinflammatory Changes and Inflammatory Response in Major Depressive Disorder
    Korkut, S.
    Kulaksizoglu, S.
    NEUROCHEMICAL JOURNAL, 2021, 15 (04) : 477 - 481